Form 4: Akero Therapeutics Chief Development Officer Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Catriona Yale, Chief Development Officer of Akero Therapeutics, sold shares of common stock between September 16 and September 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Catriona Yale, the Chief Development Officer of Akero Therapeutics, executed transactions involving the company's common stock.
- These transactions included the exercise of stock options and the subsequent sale of shares.
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2024.
- On September 16, 2024, 2,485 shares were acquired through option exercise at a price of $0.615 and sold at an average price of $27.515.
- On September 17, 2024, 2,037 shares were acquired through option exercise at a price of $0.615 and sold at an average price of $27.548.
- On September 18, 2024, 3,871 shares were acquired through option exercise at a price of $0.615 and sold at an average price of $27.56.
- Following these transactions, Yale directly owns 75,294 shares of Akero Therapeutics common stock and options to purchase 33,459 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. It doesn't provide any insight into the company's performance or future prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The use of 10b5-1 trading plans is a common strategy among corporate insiders to manage their stock holdings and comply with securities regulations.
- Comparable companies such as Viking Therapeutics, Madrigal Pharmaceuticals, and Intercept Pharmaceuticals also have executives who regularly file Form 4s related to stock transactions.
Key Dates
| Date | Description |
|---|---|
| 2024-05-28 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-09-16 | Date of first transaction: Exercise of options and sale of shares |
| 2024-09-17 | Date of second transaction: Exercise of options and sale of shares |
| 2024-09-18 | Date of third transaction: Exercise of options and sale of shares |
| 2028-10-17 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.